Vantage Hemp has submitted a Drug Master File (“DMF”) to the U.S. Food & Drug Administration (“FDA”) covering its hemp-derived cannabidiol (“CBD”) distillate. According to the announcement, the submission further reinforces Vantage as a transparent, reliable and compliant partner, committed to working with pharmaceutical companies to formulate its CBD active pharmaceutical ingredient (“API”). The filing, which also strengthens Vantage’s position as an industry leader, represents the company’s commitment to support its clients through all phases of drug development. The company also noted that it anticipates filing future DMF submissions as it works to deliver superior API quality. “Our distillate DMF filing is a testament to Vantage’s dedication to manufacturing the highest-quality CBD API,” said Vantage’s Chief Operating Officer Deepank Utkhede in the press release. “Vantage exemplifies the breadth of knowledge, depth of collaboration, and attention to detail expected and required of an API producer.”
To view the full press release, visit https://cnw.fm/yIJMq
About Vantage Hemp Co.
With large-scale extraction facilities, Colorado-based Vantage Hemp delivers pharmaceutical-grade GMP-compliant CBD extracts, including full-spectrum oil, distillate, and isolate, that companies can trust. Vantage’s contract manufacturing services offer a broad range of benefits as the company operates with integrity and abides by stringent pharmaceutical-production standards to provide quality products to its partners. For more information about the company, please visit www.VantageHemp.com
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.cannabisnewswire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.